Strutting and Fretting about Healthcare Reform

Erik Greb PharmTech editorAfter much ado, the US House of Representatives passed a healthcare-reform bill this weekend. Drugmakers and commentators are understandably eager to parse the bill to find out what it would mean for the pharmaceutical and biopharmaceutical industries. So what’s the verdict? Read more »

Same Fight, Different Day

Erik Greb PharmTech editorLast week, the Biotechnology Industry Organization (BIO) and the Generic Pharmaceutical Association (GPhA) released dueling statements about the proposal to establish an approval pathway for follow-on biologics that the Senate Committee on Health, Education, Labor, and Pensions (HELP) is considering. Are the two antagonists advancing the debate? Read more »

Chutes, Ladders, and Healthcare Reform

Erik Greb PharmTech editorCongress has taken up the Obama administration’s goal of making healthcare more affordable by introducing various strategies for reducing the cost of prescription drugs. But the Pharmaceutical Research and Manufacturers of America and the Biotechnology Industry Organization (BIO) have resisted several of Congress’s initiatives, and cost control has been elusive so far. Read more »

Would Comparative Effectiveness Reduce Patients’ Options?

Erik Greb PharmTech editorThis month, lawmakers such as Senator Kent Conrad (D-ND) and Senator Edward Kennedy (D-MA) have introduced a flurry of healthcare-reform bills that provide for comparative-effectiveness (CE) research. Supporters of CE research say that it could cut unnecessary costs by identifying the treatments that produce the best results. Federal and state governments’ share of the national healthcare bill could consequently be lighter, yet critics fear that promoting CE research could give the government too much power over treatment. Read more »

Don’t Delay Affordable Healthcare

Erik Greb PharmTech editorPresident Obama’s plan for lowering the cost of healthcare relies partly on ensuring that affordable generic drugs are available to patients. This strategy is not likely to be palatable to innovator companies, who have tried various ways of delaying generic drugs’ introduction to the market. Read more »

Are Facility Inspections a Zero-Sum Game?

Erik Greb PharmTech editorPerhaps out of embarrassment at the stream of incidents involving contaminated products, the US Food and Drug Administration has requested the largest budget increase in its history. The agency intends to use part of the funds for its proposed Safer Medical Products initiative, which will scrutinize domestic and imported drugs. Will it use the money wisely? Read more »

Sunshine in 2009

Erik Greb PharmTech editorNow is the time when the ambitious among us decide how we’re going to improve ourselves during the new year. The pharmaceutical industry is starting 2009 with an effort to reassure the public that its interactions with doctors are on the up and up. Read more »

PhRMA Votes for Itself

Erik Greb PharmTech editorThe 2008 election is only a week away, and much of the public discussion focuses on the presidential race between Obama and McCain. It’s easy to lose sight of the fact that voters will also choose their US senators and representatives. This point is not lost on the Pharmaceutical Research and Manufacturers of America (PhRMA). Read more »

« Previous Page